NEW YORK (Reuters Health) Jul 10 – Montelukast by itself or combined with loratadine has quality-of-life and clinical benefits and is well tolerated by patients with seasonal rhinitis, according to the results of a randomized trial.
Dr. Anjuli S. Nayak from the University of Illinois College of Medicine, Peoria, and colleagues from the Montelukast Fall Rhinitis Investigator Group randomly assigned 907 men and women with seasonal rhinitis to one of four treatment groups, after a 1-week, placebo run-in period.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!